Samsung Pharm (001360.KS)
SAMSUNG PHARM. Co., LTD. manufactures and sells pharmaceutical products in South Korea. It offers prescription medicines, such as anticancer immunotherapy, antipyretic analgestic and antiinflammatory, antiobesity, hypotensive, antiarteriosclerotic, digestive organs, antophlegms, enzymes, ostepoposis, and transfusion agents, as well as skeletal muscle relaxants, anti-spastic, mixed vitamins, antibiotics, and others. The company also provides medicines for digestive system, medicines for liver disorder, medicines for circulation system, cold medicines, nutritional supplements, health tonics, antophlegm agents, and others, as well as quasi-medicines, vitamins and energy drinks, and functional foods. The company was founded in 1929 and is headquartered in Hwaseong-si, South Korea.
Company Info
Highlights
₩152.19B
₩32.12B
₩14.64B
₩1,388.00 - ₩2,220.00
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
Samsung Pharm (001360.KS) returned 5.14% year-to-date (YTD) and -0.49% over the past 12 months. Over the past 10 years, 001360.KS returned -18.92% annually, underperforming the S&P 500 benchmark at 10.85%.
001360.KS
5.14%
7.66%
3.45%
-0.49%
-23.13%
-14.40%
-18.92%
^GSPC (Benchmark)
0.51%
3.96%
-2.00%
12.02%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of 001360.KS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -5.40% | 9.21% | -7.61% | 2.11% | 7.87% | 5.14% | |||||||
| 2024 | 2.43% | 5.47% | -14.72% | -4.98% | -5.41% | -5.97% | 6.87% | -0.31% | 12.04% | -14.09% | -0.26% | -1.60% | -21.63% |
| 2023 | 3.91% | -3.23% | -4.07% | 7.53% | 25.67% | -11.00% | -6.10% | -1.54% | -7.12% | -4.11% | -9.55% | -6.25% | -18.99% |
| 2022 | -16.75% | 1.46% | 5.05% | -9.15% | -0.63% | -18.88% | 8.12% | 5.35% | -21.54% | -4.90% | 4.04% | -5.12% | -45.48% |
| 2021 | 30.91% | -9.09% | -19.03% | -3.77% | 100.53% | -22.49% | -16.40% | -0.27% | -7.57% | -13.10% | -19.18% | 4.34% | -18.60% |
| 2020 | -7.27% | -11.44% | 18.58% | -1.96% | -2.62% | -4.87% | 14.56% | -6.94% | -2.28% | -8.54% | 9.34% | 56.53% | 44.22% |
| 2019 | 7.91% | 0.37% | -8.03% | 18.45% | -11.89% | -3.23% | -17.29% | 46.08% | -13.82% | 50.94% | 1.50% | 3.33% | 65.81% |
| 2018 | 11.94% | -6.33% | 7.12% | -12.96% | -7.09% | -15.72% | 7.10% | 10.95% | 8.52% | -29.06% | 7.18% | -8.33% | -31.20% |
| 2017 | -5.02% | 0.25% | -9.16% | 0.00% | 8.29% | -1.53% | -10.10% | 1.73% | -1.13% | 0.29% | 34.86% | -14.83% | -3.94% |
| 2016 | -6.09% | -20.25% | -3.19% | -1.05% | 15.00% | -10.01% | 9.22% | -19.54% | -0.89% | -25.68% | -10.91% | 13.88% | -51.25% |
| 2015 | 43.52% | 10.87% | 75.14% | 58.52% | 83.58% | -3.52% | -35.96% | 0.44% | 8.30% | 4.44% | -14.67% | -16.74% | 304.40% |
| 2014 | 46.22% | -11.28% | 21.67% | -17.98% | 56.78% | -12.52% | -13.85% | 30.74% | -16.49% | -5.66% | -9.95% | -13.33% | 22.97% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of 001360.KS is 44, indicating average performance compared to other stocks on our website. Here’s a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Samsung Pharm (001360.KS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Samsung Pharm. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Samsung Pharm was 95.36%, occurring on Sep 29, 1998. The portfolio has not yet recovered.
The current Samsung Pharm drawdown is 93.18%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -95.36% | Jun 13, 1997 | 308 | Sep 29, 1998 | — | — | — |
| -44.92% | May 14, 1996 | 159 | Jan 7, 1997 | 45 | Mar 12, 1997 | 204 |
| -25.44% | Mar 18, 1997 | 9 | Mar 28, 1997 | 50 | Jun 12, 1997 | 59 |
| -23.65% | Dec 6, 1995 | 18 | Jan 5, 1996 | 30 | Feb 16, 1996 | 48 |
| -18.99% | Feb 26, 1996 | 24 | Mar 29, 1996 | 13 | Apr 19, 1996 | 37 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Samsung Pharm over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Samsung Pharm, comparing actual results with analytics estimates.
Valuation
The Valuation section provides an overview of how Samsung Pharm is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for 001360.KS compared to other companies in the Drug Manufacturers - Specialty & Generic industry. 001360.KS currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for 001360.KS relative to other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 001360.KS has a P/S ratio of 3.4. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for 001360.KS in comparison with other companies in the Drug Manufacturers - Specialty & Generic industry. Currently, 001360.KS has a P/B value of 1.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |